CHMP recommends eight new drugs for approval – one cancer drug rejected

The expert panel at the EMA recommended eight new drugs for approval at its meeting in June, and backed extensions of therapeutic indication for six existing treatments.


European practitioners will gain new methods for treatment after the June meeting of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) where the panel recommended several novel drug candidates and new indications for existing drugs.

Celgene's gene therapy Abecma (idecabtagene vicleucel) was for example nominated for conditional marketing authorization as a fourth-line therapy for bone marrow cancer. CHMP also had a positive view of Biomarin's Voxzogo (vosoritid) for the day-to-day treatment of children with achondroplasia. This drug might eventually challenge Transcon CNP, which is produced by Danish biotech firm Ascendis, if the latter reaches the market.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs